Boston Scientific Corporation (NYSE: BSX) finished Thursday’s session (December 18, 2025) on a strong note, and early after-hours trading was notably calm—an important tell for investors heading into Friday’s open (December 19). Shares closed at $96.11, up 1.73%, marking a third straight daily gain in a broadly higher market session.
Below is a roundup of what moved BSX today, what Wall Street forecasts look like after fresh analyst updates, and the practical “before-the-bell” checklist for Friday.
BSX stock after the bell: the Thursday, Dec. 18 recap
Regular session (4:00 p.m. ET close):
- Close: $96.11 (+1.73%)
- Volume: about 15.6 million shares, well above the stock’s 50-day average (around 9 million), suggesting elevated participation rather than a quiet drift higher.
- BSX ended the day roughly 12.23% below its 52-week high of $109.50 (set September 9).
After-hours (as of 6:00 p.m. ET):
- BSX traded at $96.18, up $0.07 (+0.07%) from the close, and ranged between $96.11 and $96.46 in the early extended session.
That modest after-hours change matters: it suggests no major late-breaking company headline was forcing rapid repricing immediately after the closing bell.
Why Boston Scientific rose today: broad risk-on tone plus medtech-relative strength
Thursday wasn’t a BSX-only story. The overall tape was positive, with the S&P 500 up 0.79% and the Dow up 0.14%—a supportive backdrop for large-cap healthcare and medtech alike.
Within the group, BSX also outperformed key competitors on the day, including Abbott (ABT) (down) while Medtronic (MDT) and Stryker (SYK) posted smaller gains.
One additional macro tailwind investors cited across markets: the day’s inflation narrative. Several outlets reported that November inflation readings appeared softer than expected, though economists warned the data may be distorted after the recent government shutdown disrupted normal collection and reporting.
For BSX specifically, the “so what” is straightforward: lower-rate expectations (even marginally) tend to support longer-duration growth stories, and Boston Scientific has been priced by many investors as a steady, innovation-led compounder in cardiovascular and electrophysiology.
Analyst forecasts changed today: Truist cut its target, but Street consensus remains bullish
The biggest stock-specific “new” item investors saw today was not a product announcement—it was fresh sell-side positioning.
Truist trims its price target (still bullish)
MarketScreener/MT Newswires reported Thursday that Truist Securities lowered its price target to $120 from $130, while maintaining a Buy rating.
MarketBeat separately echoed the same target change and Buy stance in a Thursday note recap.
A lower target with a maintained Buy rating often signals:
- the analyst still likes the business, but
- is expressing more caution on near-term valuation, multiples, or 2026 setup.
UBS stays constructive with a higher target
An Investing.com report (citing UBS) reiterated a Buy stance and referenced a $140 price target, highlighting Boston Scientific’s WATCHMAN franchise and longer-run expectations around growth drivers into 2026.
UBS also flagged an important nuance for 2026 watchers: it expects the Electrophysiology (EP) division to slow versus very strong recent growth rates, while still pointing to the company’s intent to grow EP above broader market rates.
Where the broader Street stands tonight
MarketScreener’s consensus snapshot showed:
- Mean consensus:BUY
- Number of analysts:34
- Average target price:$126.17 (about +31% over the latest close shown there)
So even with today’s target cut from Truist, the broader analyst picture still reads as constructively tilted, with targets clustering well above current trading levels.
A competitive headline investors may connect to BSX: pulsed field ablation keeps heating up
A MedTech Dive report published Thursday said Pulse Biosciences received FDA IDE clearance to begin a study of its cardiac ablation catheter system for paroxysmal atrial fibrillation—part of the broader momentum in pulsed field ablation (PFA).
The relevance to Boston Scientific is that PFA has been one of the most watched growth arenas in electrophysiology, and MedTech Dive explicitly noted that new PFA devices have been driving strong sales growth for Boston Scientific and Medtronic.
For BSX investors, that’s a two-sided signal:
- Positive: it reinforces that PFA is a high-priority clinical/market trend with expanding procedure adoption.
- Competitive risk: more FDA-authorized studies and more platforms in the pipeline typically mean a more crowded landscape over time.
Options market snapshot: traders are clustering around the $95–$100 zone
Options activity can be noisy, but it often reveals where positioning is concentrated.
Benzinga’s options-flow analysis published Thursday suggested “whales” have been eyeing a $95–$100 window based on volume/open interest, alongside a tilt that included a meaningful amount of bearish positioning in the trades they tracked. Benzinga
How to interpret that heading into Friday:
- The $95 area can behave like a psychological support zone (and a hedging strike).
- The $100 area is a natural “round-number” magnet where calls/puts often build—sometimes acting as a near-term ceiling unless a catalyst breaks it.
This is not a forecast by itself, but it can help explain why BSX may trade “sticky” around these levels absent fresh news.
What to know before the market opens Friday, Dec. 19, 2025
Here’s the practical pre-open checklist for BSX traders and longer-term holders.
1) The after-hours tape is quiet—so watch premarket headlines
As of early after-hours, BSX was only slightly higher than the regular close, with a tight trading range.
That typically means Friday’s direction could be more sensitive to:
- broad market futures tone,
- rate moves,
- any overnight medtech/regulatory headlines,
- additional analyst notes hitting the wires premarket.
2) Key 10:00 a.m. ET economic releases could move the whole tape
Even though these hit after the opening bell, they can still swing the market during the morning session:
- Existing-Home Sales (November 2025) will be released Friday, Dec. 19 at 10:00 a.m. ET, according to the National Association of Realtors.
- The University of Michigan Surveys of Consumers site lists the Final December consumer sentiment data as the next release at 10:00 a.m. ET on Dec. 19.
- The BLS “Schedule of Selected Releases” also shows multiple releases set for Friday, Dec. 19 at 10:00 a.m., including Consumer Expenditures (Annual 2024) and other datasets. bls.gov
For BSX, the mechanism is indirect: these releases can move yields and indexes, and BSX frequently trades with the broader “quality growth healthcare” basket on macro days.
3) Fed and policy chatter remains a background volatility factor
Reuters reported Thursday that President Donald Trump said he interviewed Fed Governor Christopher Waller as a potential candidate to replace Jerome Powell as Fed chair when Powell’s term expires in May.
Even without immediate policy changes, leadership speculation can ripple into rate expectations—another indirect driver for large-cap growth stocks.
4) Don’t ignore the holiday trading schedule as liquidity shifts into late December
This won’t affect Friday’s open directly, but it matters for planning trades and expectations for spreads/volume next week:
- Reuters reported that major U.S. exchanges said markets will remain open on Dec. 24 and Dec. 26, even after a federal holiday directive for those dates.
- The NYSE calendar confirms an early close at 1:00 p.m. ET on Wednesday, Dec. 24, 2025.
- Nasdaq Trader’s holiday calendar likewise lists Dec. 24, 2025 as an early close at 1:00 p.m.
Late-December trading often brings thinner liquidity, which can exaggerate moves—especially on analyst notes or sector headlines.
The next big company catalyst: Q4 earnings season is approaching
While tonight’s action is about price/positioning, the next “hard catalyst” is earnings.
Multiple earnings calendars currently point to Feb. 4, 2026 as the expected next earnings date for Boston Scientific (often listed as “before market open,” though schedules can change). Nasdaq+1
Investors going into that report will likely anchor to the company’s most recent guidance posture: Reuters reported in October that Boston Scientific raised its 2025 adjusted EPS outlook and guided Q4 adjusted EPS to 77–79 cents at that time, following strong Q3 demand for heart devices.
Bottom line: what matters most for BSX going into Friday’s open
Boston Scientific stock heads into Friday (Dec. 19) with three things standing out:
- Momentum: a third consecutive up day, on above-average volume.
- Forecasts: Truist trimmed its target, but broader analyst consensus remains Buy-leaning with targets well above today’s close.
- Catalyst watch: no obvious after-hours bombshell, so Friday may hinge more on macro releases (10:00 a.m. ET) and any premarket medtech headlines than on a single BSX-specific event.
